Effect of recombinant epidermal growth factor on ocular surface re-epithelization following amniotic membrane transplantation in patients with pterygium excision.
To observe the effect of recombinant human epidermal growth factor (rhEGF) on ocular surface re-epithelization and the efficacy of amniotic membrane transplantation in patients with pterygium. Amniotic membrane transplantation was performed on 40 eyes of 36 patients with pterygium after removal of pterygium. All the eyes were randomly divided into 2 groups: 20 eyes received rhEGF ophthalmic solution and the other 20 drug vehicle. The healing rates of the corneal and conjunctival epithelium were observed respectively. Follow-up study lasting for 3 to 12 months was conducted in all the cases postoperatively. The healing rate of both the corneal and conjunctival epithelium in rhEGF-treated group (74.983+/-18.998 micrometer/h and 36.584+/-7.888 micrometer/h respectively) was significantly faster than the control (59.372+/-17.197 +/-m/h and 29.18+/-5.450 micrometer/h respectively, P<0.01 for both comparisons). Follow-up witnessed no recurrence of the disease. rhEGF effectively promotes the healing of ocular surface epithelium defect, and amniotic membrane transplantation is a good surgical procedure for treating pterygium.